Literature DB >> 4413334

Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

K Irie, R F Irie, D L Morton.   

Abstract

The immune adherence test was used to determine whether antibody and complement in cancer patients are fixed in vivo to tumor cells. Human erythrocytes adhered in vitro to the surface of human cancer cells obtained from autopsy and biopsy. Adherence was enhanced by further addition of the C2 and C3 components of complement, and was diminished by preliminary treatment with antibody to C3 (that is, to beta1C-globulin). The results suggest that tumor associated membrane antigens form complexes in vivo with antibodies and complement.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4413334     DOI： 10.1126/science.186.4162.454

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  11 in total

1.  Immune adherence reactivity of rat alveolar macrophages following inhalation of crocidolite asbestos.

Authors:  K Miller; E Kagan
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

2.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 3.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

4.  Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.

Authors:  R F Irie; L L Sze; R E Saxton
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Ganglioside GM2 as a human tumor antigen (OFA-I-1).

Authors:  T Tai; J C Paulson; L D Cahan; R F Irie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

7.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

8.  Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.

Authors:  N A Carpentier; G T Lange; D M Fiere; G J Fournie; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

9.  Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system.

Authors:  R A Clark; S J Klebanoff
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Immunoadherence and complement in cancer-bearing mice.

Authors:  C Porta; M L Villa; E Clerici
Journal:  Br J Cancer       Date:  1978-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.